This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
5-Hydroxytryptophan: Difference between revisions
>Isaak Annotate SSRI interaction and SNRI interaction analogous to other articles (e.g. MDMA) |
>Blackhole added important category |
||
| (5 intermediate revisions by 4 users not shown) | |||
| Line 84: | Line 84: | ||
It has been suggested that 5-HTP may cause eosinophilia-myalgia syndrome (EMS), a serious condition which results in extreme muscle tenderness, myalgia, and blood abnormalities. However, there is evidence to show that EMS was likely caused by a contaminant in certain 5-HTP supplements instead of the substance itself.<ref>{{cite journal | vauthors=((Michelson, D.)), ((Page, S. W.)), ((Casey, R.)), ((Trucksess, M. W.)), ((Love, L. A.)), ((Milstien, S.)), ((Wilson, C.)), ((Massaquoi, S. G.)), ((Crofford, L. J.)), ((Hallett, M.)) | journal=The Journal of Rheumatology | title=An eosinophilia-myalgia syndrome related disorder associated with exposure to L-5-hydroxytryptophan | volume=21 | issue=12 | pages=2261–2265 | date= December 1994 | issn=0315-162X}}</ref> | It has been suggested that 5-HTP may cause eosinophilia-myalgia syndrome (EMS), a serious condition which results in extreme muscle tenderness, myalgia, and blood abnormalities. However, there is evidence to show that EMS was likely caused by a contaminant in certain 5-HTP supplements instead of the substance itself.<ref>{{cite journal | vauthors=((Michelson, D.)), ((Page, S. W.)), ((Casey, R.)), ((Trucksess, M. W.)), ((Love, L. A.)), ((Milstien, S.)), ((Wilson, C.)), ((Massaquoi, S. G.)), ((Crofford, L. J.)), ((Hallett, M.)) | journal=The Journal of Rheumatology | title=An eosinophilia-myalgia syndrome related disorder associated with exposure to L-5-hydroxytryptophan | volume=21 | issue=12 | pages=2261–2265 | date= December 1994 | issn=0315-162X}}</ref> | ||
===Dangerous interactions=== | ===Dangerous interactions=== | ||
Although many substances are safe on their own, they can become dangerous and even life-threatening when combined with other substances. The list below contains some common potentially dangerous combinations, but may not include all of them. Certain combinations may be safe in low doses of each but still increase the potential risk of death. Independent research should always be done to ensure that a combination of two or more substances is safe before consumption. | Although many substances are safe on their own, they can become dangerous and even life-threatening when combined with other substances. The list below contains some common potentially dangerous combinations, but may not include all of them. Certain combinations may be safe in low doses of each, but still increase the potential risk of death. Independent research should always be done to ensure that a combination of two or more substances is safe before consumption. | ||
Combinations in the list below may increase the amount of neurotransmitters, such as serotonin, to dangerous or even fatal levels, resulting in life-threatening [[serotonin syndrome]]. | Combinations in the list below may increase the amount of neurotransmitters, such as serotonin, to dangerous or even fatal levels, resulting in life-threatening [[serotonin syndrome]]. | ||
| Line 90: | Line 90: | ||
*'''[[DangerousInteraction::SSRIs]]''' - When combined with antidepressants of the SSRI class, high doses of 5-HTP can cause acute serotonin syndrome in rats.<ref name="one">{{cite journal | vauthors=((Ma, Z.)), ((Zhang, G.)), ((Jenney, C.)), ((Krishnamoorthy, S.)), ((Tao, R.)) | journal=European Journal of Pharmacology | title=Characterization of serotonin-toxicity syndrome (toxidrome) elicited by 5-hydroxy-l-tryptophan in clorgyline-pretreated rats | volume=588 | issue=2–3 | pages=198–206 | date=7 July 2008 | issn=0014-2999 | doi=10.1016/j.ejphar.2008.04.004}}</ref><ref name="two">{{cite journal | vauthors=((Izumi, T.)), ((Iwamoto, N.)), ((Kitaichi, Y.)), ((Kato, A.)), ((Inoue, T.)), ((Koyama, T.)) | journal=European Journal of Pharmacology | title=Effects of co-administration of a selective serotonin reuptake inhibitor and monoamine oxidase inhibitors on 5-HT-related behavior in rats | volume=532 | issue=3 | pages=258–264 | date=27 February 2006 | issn=0014-2999 | doi=10.1016/j.ejphar.2005.12.075}}</ref> | *'''[[DangerousInteraction::SSRIs]]''' - When combined with antidepressants of the SSRI class, high doses of 5-HTP can cause acute serotonin syndrome in rats.<ref name="one">{{cite journal | vauthors=((Ma, Z.)), ((Zhang, G.)), ((Jenney, C.)), ((Krishnamoorthy, S.)), ((Tao, R.)) | journal=European Journal of Pharmacology | title=Characterization of serotonin-toxicity syndrome (toxidrome) elicited by 5-hydroxy-l-tryptophan in clorgyline-pretreated rats | volume=588 | issue=2–3 | pages=198–206 | date=7 July 2008 | issn=0014-2999 | doi=10.1016/j.ejphar.2008.04.004}}</ref><ref name="two">{{cite journal | vauthors=((Izumi, T.)), ((Iwamoto, N.)), ((Kitaichi, Y.)), ((Kato, A.)), ((Inoue, T.)), ((Koyama, T.)) | journal=European Journal of Pharmacology | title=Effects of co-administration of a selective serotonin reuptake inhibitor and monoamine oxidase inhibitors on 5-HT-related behavior in rats | volume=532 | issue=3 | pages=258–264 | date=27 February 2006 | issn=0014-2999 | doi=10.1016/j.ejphar.2005.12.075}}</ref> | ||
*'''[[DangerousInteraction::SNRIs]]''' | *'''[[DangerousInteraction::SNRIs]]''' | ||
*'''[[DangerousInteraction::Serotonin releasers]]''' such as '''[[MDMA]]''', '''[[4-FA]]''', '''[[MDAI]]''' and '''[[αMT]]''' - To prevent serotonin syndrome, 5-HTP should only be taken once the user has come down from the MDMA (or other serotonin releaser), roughly 12 hours after the last dose. | *'''[[DangerousInteraction::Serotonin releasers]]''' such as '''[[MDMA]]''', '''[[mephedrone]]''', '''[[4-FA]]''', '''[[MDAI]]''' and '''[[αMT]]''' - To prevent serotonin syndrome, 5-HTP should only be taken once the user has come down from the MDMA (or other serotonin releaser), roughly 12 hours after the last dose. | ||
*'''[[DangerousInteraction::MAOIs]]''' such as '''[[syrian rue]]''', '''[[banisteriopsis caapi]]''', '''[[2C-T-2]]''', '''[[2C-T-7]]''', '''[[αMT]]''', and some '''[[antidepressants]]''' - When combined with antidepressants of the MAOI class, high doses of 5-HTP can cause acute serotonin syndrome in rats.<ref name="one" /><ref name="two" /> | *'''[[DangerousInteraction::MAOIs]]''' such as '''[[syrian rue]]''', '''[[banisteriopsis caapi]]''', '''[[2C-T-2]]''', '''[[2C-T-7]]''', '''[[αMT]]''', and some '''[[antidepressants]]''' - When combined with antidepressants of the MAOI class, high doses of 5-HTP can cause acute serotonin syndrome in rats.<ref name="one" /><ref name="two" /> | ||
*'''[[DangerousInteraction::Tricyclic antidepressants]] (TCAs)''' | *'''[[DangerousInteraction::Tricyclic antidepressants]] (TCAs)''' | ||
| Line 96: | Line 96: | ||
==Legal status== | ==Legal status== | ||
5-HTP is commonly sold over the counter as a dietary supplement in the United States, United Kingdom, and | 5-HTP is commonly sold over the counter as a dietary supplement in the United States, United Kingdom, Canada and most of Europe and is not subject to any illicit substance control laws. | ||
In some parts of Europe, where it prescribed as an | In some parts of Europe, where it prescribed as an anti-depressant, there may be some controls on its sale and distribution.{{citation needed}} | ||
==See also== | ==See also== | ||
| Line 114: | Line 114: | ||
*[https://isomerdesign.com/PiHKAL/explore.php?id=5149 5-Hydroxytryptophan (Isomer Design)] | *[https://isomerdesign.com/PiHKAL/explore.php?id=5149 5-Hydroxytryptophan (Isomer Design)] | ||
*[http://umm.edu/health/medical/altmed/supplement/5hydroxytryptophan-5htp 5-Hydroxytryptophan (UM Medical Center)] | *[http://umm.edu/health/medical/altmed/supplement/5hydroxytryptophan-5htp 5-Hydroxytryptophan (UM Medical Center)] | ||
*[https://go.drugbank.com/drugs/DB02959 5-HTP (DrugBank)] | |||
*[https://examine.com/supplements/5-htp/ 5-HTP (Examine.com)] | *[https://examine.com/supplements/5-htp/ 5-HTP (Examine.com)] | ||
*[https://www.drugs.com/npp/5-htp.html 5-HTP (Drugs.com)] | *[https://www.drugs.com/npp/5-htp.html 5-HTP (Drugs.com)] | ||
| Line 119: | Line 120: | ||
==References== | ==References== | ||
<references /> | <references /> | ||
[[Category:Psychoactive substance]] | |||
[[Category:Amino acid]] | [[Category:Amino acid]] | ||
[[Category:Tryptamine]] | [[Category:Tryptamine]] | ||
[[Category:Antidepressant]] | [[Category:Antidepressant]] | ||
[[Category:Precursor]] | [[Category:Precursor]] | ||